Steroid Dosing for Acute CPPD Arthritis

Introduction to Steroid Treatment

• The European League Against Rheumatism (EULAR) guidelines recommend a short tapering course of oral glucocorticosteroids as effective for acute CPPD not amenable to intra-articular injection 1, 2, 3

Intra-articular Steroids

• Intra-articular injection of long-acting glucocorticosteroids is the optimal first-line treatment for monoarticular or oligoarticular acute CPPD arthritis, combined with joint aspiration, ice application, and temporary rest 1, 2, 4
• Intra-articular injection alone may be sufficient without requiring systemic therapy for many patients 2, 3
• Triamcinolone acetonide 60 mg intramuscularly showed at least 50% clinical improvement in all patients within 14 days 3
• Betamethasone 7 mg intramuscularly or methylprednisolone 125 mg intravenously as single doses showed significant improvement compared to NSAIDs on day 1 3

Oral Systemic Steroids

• Prednisone or prednisolone at 0.5 mg/kg/day for 5-10 days, then discontinue, is a recommended regimen 5
• Alternative regimen: full dose for 2-5 days, then taper over 7-10 days before discontinuation 5
• Oral methylprednisolone dose pack is an appropriate option based on current clinical practice patterns 5

Parenteral Steroids

• Intramuscular triamcinolone acetonide 60 mg as a single dose, followed by oral prednisone/prednisolone, is an appropriate alternative regimen 5
• Parenteral ACTH 40-80 units has been used successfully in retrospective studies of acute crystal arthritis 3

Key Clinical Considerations

• The evidence for steroid dosing in CPPD is largely extrapolated from gout studies, with a level of evidence of IIb-III for systemic steroids in CPPD 1, 2, 3, 6
• Steroids are particularly valuable in older patients with comorbidities who have contraindications to NSAIDs or colchicine 1, 2, 6

Critical Pitfalls to Avoid

• Do not use prolonged courses of steroids without a clear tapering plan, as this increases adverse effects without additional benefit 5
• Always exclude septic arthritis before injecting steroids into a joint, particularly in monoarticular presentations 2, 6
• Assess cardiovascular, renal, and metabolic comorbidities before selecting steroid dose and duration, especially in elderly patients 1, 6

Treatment of Suspected CPPD in Older Adults with Renal Impairment

Initial Treatment Approach

• The American College of Rheumatology recommends systemic glucocorticosteroids, such as prednisone 0.5 mg/kg/day for 5-10 days, as the optimal first-line treatment for older adults with suspected CPPD and impaired renal function, offering the best benefit-risk ratio while avoiding the significant toxicity risks of NSAIDs and colchicine in this vulnerable population, with a strength of evidence of Level IIb-III and 87% strength of recommendation 7
• Systemic steroids are particularly valuable in older patients with comorbidities and renal impairment who have contraindications to NSAIDs or colchicine, with evidence supporting their use from a non-randomized trial demonstrating at least 50% improvement on day 1 with NNT=3 (95% CI 2-16) compared to NSAIDs 8

Why Avoid NSAIDs and Colchicine in This Patient

• NSAIDs are contraindicated or high-risk due to abundant evidence of gastrointestinal bleeding, cardiovascular events, and renal impairment, particularly in older patients with chronic renal impairment who have a greatly increased likelihood of toxicity 7
• Colchicine requires extreme caution with renal impairment, with a 100% incidence of side effects with traditional dosing regimens, and a recommended starting dose of 0.3 mg/day for severe renal impairment (CrCl <30 mL/min) 7

Prophylaxis Against Recurrent Attacks

• For patients with normal-to-mild renal impairment (CrCl 50-80 mL/min), low-dose colchicine 0.5-1 mg daily with close monitoring is recommended for prophylaxis against recurrent attacks 7

Critical Pitfalls to Avoid

• Do not use traditional high-dose colchicine regimens (1 mg loading then 0.5 mg every 2 hours) due to a 100% incidence of marked side effects, and never use intravenous colchicine due to a high risk of serious toxicity and fatality 7

Strength of Evidence Limitations

• The majority of CPPD treatment recommendations are based on expert opinion (Level IV evidence) and extrapolation from gout studies, with only 3-4 RCTs existing for CPPD treatment, highlighting the need for further research in this area 7, 9

Management of Acute Crystalline Arthritis in Patients with NSAID Allergy

Diagnosis and Initial Assessment

• Before any anti‑inflammatory therapy, septic arthritis must be ruled out by joint aspiration with synovial fluid analysis and culture in patients presenting with acute crystalline arthritis and fever. 10

First‑Line Intra‑Articular Therapy (Mono‑/Oligoarticular Disease)

• In patients where infection has been excluded, a single intra‑articular injection of a long‑acting glucocorticosteroid (e.g., triamcinolone acetonide 60 mg) is recommended as the initial treatment. 10
• This intra‑articular approach yields clinical improvement in at least 50 % of patients within 14 days and often eliminates the need for systemic medication. [11][10]

Systemic Glucocorticosteroid Therapy (Polyarticular Disease or When Intra‑Articular Injection Is Not Feasible)

• A single parenteral dose of betamethasone 7 mg intramuscularly or methylprednisolone 125 mg intravenously provides rapid pain relief, achieving a number‑needed‑to‑treat of 3 on day 1 (95 % CI 2–16) compared with NSAIDs. [10][11]
• Systemic glucocorticosteroids are endorsed for NSAID‑intolerant patients with a strength of recommendation of 87 % in the EULAR guidelines. 10

Alternative Parenteral Option: ACTH

• Administration of ACTH 40–80 units (IV/IM/SC) three times resolves acute attacks in an average of 4.2 days; reported adverse effects are mild hypokalemia, hyperglycemia, and fluid retention. [11][12]10

Role of Colchicine

• Traditional colchicine dosing is associated with a 100 % incidence of side effects and is not advised for severe acute attacks requiring rapid control. [11][10]
• Colchicine is reserved for prophylaxis of recurrent attacks, typically at 0.5–1 mg daily when renal function allows. [12][10]

Evidence Summary

• A non‑randomized trial demonstrated that glucocorticoid injections are more effective than NSAIDs for achieving quick control of severe pain on day 1. [11][10]
• In the acute setting, glucocorticosteroids are generally well tolerated, with only minor side effects such as profuse sweating and hot flushes reported. [11][10]

Monitoring and Safety

• Patients receiving systemic glucocorticoids should be monitored for common steroid‑related complications, including hyperglycemia, hypokalemia, fluid retention, and hypertension. [11][10]
• After resolution of the acute episode, low‑dose colchicine prophylaxis (0.5–1 mg daily) may be considered if renal function is adequate. [12][10]